IGC Pharma Expands AI Platform with Advanced Diagnostic Model for Alzheimer’s and Dementia Detection
POTOMAC, MARYLAND – March 4, 2025 – IGC Pharma, Inc. (“IGC†or the “Companyâ€) (NYSE American: IGC) today announced an advancement in its Artificial Intelligence (“AIâ€) platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer’s disease (AD) and other causes of dementia. With Alzheimer’s accounting for approximately 60-80% […]
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer’s Disease
January 28, 2025 – The “Company” is proud to announce its selection as one of the top 15 finalists in the PREPARE Challenge – Phase 2: Model Arena (Acoustic Track), organized by the National Institute on Aging (NIA). This recognition highlights IGC’s innovative application of artificial intelligence (AI) and machine learning to advance early detection […]
IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist
Artificial Intelligence Modelling Reveals New Possibilities for Metabolic and Neurological Therapies
IGC Pharma Adds Advisor in Artificial Intelligence
April, 9, 2024 – The “Company” today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AIâ€) and one of the world’s top researchers. Dr. Arbelaez will support the development of the Phase 2 clinical trial of IGC-AD1, IGC Pharma’s lead therapeutic candidate targeting agitation in Alzheimer’s disease. Recent interim results from […]